2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2007020256v1 18/10/2766    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perkovic, V. Articles by Chalmers, J. Search for Related Content PubMed PubMed Citation Articles by Perkovic, V. Articles by Chalmers, J.

Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering: Data from the PROGRESS Study

Vlado Perkovic^*,, Toshiharu Ninomiya^*, Hisatomi Arima^*, Martin Gallagher^*, Meg Jardine^*, Alan Cass^*,, Bruce Neal^*, Stephen MacMahon^*, and John Chalmers^*,

^* George Institute for International Health, University of Sydney, Royal North Shore Hospital, and Royal Prince Alfred Hospital, Sydney, Australia

Correspondence: Dr. Vlado Perkovic, George Institute for International Health, PO Box M201, Sydney, Australia, 2050. Phone: +612-9993-4523; Fax: +612-9993-4501; E-mail: vperkovic{at}thegeorgeinstitute.org

Received for publication February 28, 2007. Accepted for publication May 24, 2007.

Chronic kidney disease (CKD) is associated with a high risk of cardiovascular disease, but evidence regarding the effectiveness of interventions to reduce that risk is lacking. The Perindopril Protection against Recurrent Stroke Study (PROGRESS) study enrolled 6105 participants with cerebrovascular disease and randomly allocated them to perindopril-based blood pressure–lowering therapy or placebo. Individuals with CKD were at approximately 1.5-fold greater risk of major vascular events, stroke, and coronary heart disease, and were more than twice as likely to die (all P0.002). Perindopril-based treatment reduced the risk of major vascular events by 30% and stroke by 35% among subjects with CKD, and the absolute effects of treatment were 1.7-fold greater for those with CKD than for those without. Considering patients with CKD and a history of cerebrovascular disease, perindopril prevented one stroke or other cardiovascular event among every 11 patients treated over five years. In conclusion, kidney function should be considered when determining the need for blood pressure lowering therapy in patients with cerebrovascular disease.

This article has been cited by other articles:

				N. Richards, K. Harris, M. Whitfield, D. O'Donoghue, R. Lewis, M. Mansell, S. Thomas, J. Townend, M. Eames, and D. Marcelli Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes Nephrol. Dial. Transplant., February 1, 2008; 23(2): 549 - 555. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673